Stroke or transient ischaemic attack · people with cerebral small vessel disease and no dementia
1 finding from 1 review
Any adverse events (excluding major bleeding) · people with cerebral small vessel disease and no dementia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawal from study medication · people with cerebral small vessel disease and no dementia
1 finding from 1 review
All‐cause mortality · heart failure associated with central sleep apnoea
It is very uncertain whether PAP therapy changes all‐cause mortality compared with usual care (very low certainty).
1 finding from 1 review
Cardiac disease‐ related mortality · heart failure associated with central sleep apnoea
PAP therapy showed no clear difference in cardiac‐related mortality compared with usual care (moderate certainty).
1 finding from 1 review
Patient readmissions · heart failure associated with central sleep apnoea
PAP therapy showed no clear difference in all‐cause rehospitalisation compared with usual care (low certainty).
1 finding from 1 review
Cardiac‐related rehospitalisation · heart failure associated with central sleep apnoea
PAP therapy showed no clear difference in cardiac‐related rehospitalisation compared with usual care (low certainty).
1 finding from 1 review
QoL · heart failure associated with central sleep apnoea
2 findings from 1 review
Adverse events · heart failure associated with central sleep apnoea
1 finding from 1 review
Specific adverse events: serious haemorrhage · women with persistent, recurrent, or metastatic cervical cancer
It is very uncertain whether cediranib plus chemotherapy changes specific adverse events: serious haemorrhage compared with placebo plus chemotherapy (very low certainty).
1 finding from 1 review
Specific adverse events: serious thromboembolic events · women with persistent, recurrent, or metastatic cervical cancer
It is very uncertain whether cediranib plus chemotherapy changes specific adverse events: serious thromboembolic events compared with placebo plus chemotherapy (very low certainty).
1 finding from 1 review
Specific adverse events: serioushypertension · women with persistent, recurrent, or metastatic cervical cancer
It is very uncertain whether cediranib plus chemotherapy changes specific adverse events: serioushypertension compared with placebo plus chemotherapy (very low certainty).
1 finding from 1 review
Serious adverse events · women with persistent, recurrent, or metastatic cervical cancer
Cediranib plus chemotherapy showed no clear difference in serious adverse events compared with placebo plus chemotherapy (low certainty).
1 finding from 1 review
Economic evaluation ‐ not measured · women with persistent, recurrent, or metastatic cervical cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival · women with persistent, recurrent, or metastatic cervical cancer
Cediranib plus chemotherapy showed no clear difference in overall survival compared with placebo plus chemotherapy (low certainty).
1 finding from 1 review
Specific adverse events: gastrointestinal perforations or fistulae · women with persistent, recurrent, or metastatic cervical cancer
It is very uncertain whether cediranib plus chemotherapy changes specific adverse events: gastrointestinal perforations or fistulae compared with placebo plus chemotherapy (very low certainty).
1 finding from 1 review
Pelvic pain · women having endometriosis surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pelvic pain · women having endometriosis surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain recurrence (dichotomous) Pain recurrence ≤ 12 months · women having endometriosis surgery
Presurgical medical therapy showed no clear difference in pain recurrence (dichotomous) Pain recurrence ≤ 12 months compared with postsurgical medical therapy (low certainty).
1 finding from 1 review
Disease recurrence at 12 months – total (AFS score) · women having endometriosis surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found